Information on EC 3.4.23.46 - memapsin 2

New: Word Map on EC 3.4.23.46
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota

EC NUMBER
COMMENTARY hide
3.4.23.46
-
RECOMMENDED NAME
GeneOntology No.
memapsin 2
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
broad endopeptidase specificity. Cleaves Glu-Val-Asn-Leu-/-Asp-Ala-Glu-Phe in the Swedish variant of Alzheimer's amyloid precursor protein
show the reaction diagram
CAS REGISTRY NUMBER
COMMENTARY hide
158736-49-3
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
BalbC mice
SwissProt
Manually annotated by BRENDA team
var. acuta
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
-
BACE1 heterozygous deletion rescues conditioned taste aversion memory deficits in 5XFAD mice
metabolism
-
BACE1 is responsible for the first step in the production of the beta-amyloid protein of Alzheimer's disease
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
((7-methoxycoumarin-4-yl)acetyl)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(2,4-dinitrophenyl) + H2O
((7-methoxycoumarin-4-yl)acetyl)-Ser-Glu-Val-Asn-Leu + Asp-Ala-Glu-Phe-Lys(2,4-dinitrophenyl)
show the reaction diagram
((7-methoxycoumarin-4-yl)acetyl)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(2,4-dinitrophenyl)-Arg-Arg-NH2 + H2O
((7-methoxycoumarin-4-yl)acetyl)-Ser-Glu-Val-Asn-Leu + Asp-Ala-Glu-Phe-Lys(2,4-dinitrophenyl)-Arg-Arg-NH2
show the reaction diagram
-
synthesis, structure and potencies of beta-secretase BACE1 inhibitors optimized, effects of P4 modification on BACE1 inhibitory activity analyzed
-
-
?
(7-methoxycoumarin-4-yl)-acetyl-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-Lys-(2,4-dinitrophenyl)-Arg-Arg-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)acetyl-L-Ser-L-Glu-L-Val-L-Asn-L-Leu-L-Asp-L-Ala-L-Glu-L-Phe-L-Lys-dinitrophenyl + H2O
?
show the reaction diagram
-
-
-
-
?
7-amido-4-methylcoumarin-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-(Lys-2,4-dinitrophenyl)-OH + H2O
?
show the reaction diagram
-
-
-
-
?
7-amido-4-methylcoumarin-Glu-Val-Lys-Met-Asp-Ala-Glu-Phe-(Lys-2,4-dinitrophenyl)-OH + H2O
?
show the reaction diagram
-
-
-
-
?
7-amido-4-methylcoumarin-SEVNLDAEFRK-(2,4-dinitrophenyl)-RR-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
7-methoxycoumarin-4-yl-acetyl-SEVNLDAEFR-(2,4-dinitrophenyl)K-RR + H2O
?
show the reaction diagram
-
-
-
-
?
7-methoxycoumarin-4-yl-SEVNLDAEFK-2,4-dinitrophenyl-RR + H2O
?
show the reaction diagram
-
-
-
-
?
Abz-SEVNLDAEFR-Dpa + H2O
?
show the reaction diagram
amyloid -like PROTEIN 2 + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid beta-precursor protein + H2O
?
show the reaction diagram
amyloid pbeta A4 protein + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
?
show the reaction diagram
amyloid precursor protein + H2O
amyloid beta protein 40 + amyloid beta protein 42
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
amyloid protein 1-42 + ?
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
beta-amyloid peptide 40 + beta-amyloid peptide 42
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
C-terminal fragment + soluble N-terminal fragment APPbeta
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
C-terminal fragment C99 of amyloid precursor protein + ?
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
amyloid precursor protein + H2O
neurotrophic soluble amyloid precursor protein + ?
show the reaction diagram
-
-
-
-
?
amyloid precursor protein-DELTANL + H2O
?
show the reaction diagram
-
the Swedish familial mutation in APP (DELTANL) enhances beta-secretase cleavage
-
-
?
amyloid-beta precursor protein + H2O
amyloid-beta protein 40 + amyloid-beta protein 42
show the reaction diagram
-
-
-
-
?
amyloid-beta precursor protein + H2O
fragments of amyloid-beta precursor protein
show the reaction diagram
amyloid-like protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
Arg-Glu(5-[(2-aminoethyl)amino]-naphthalene-1-sulfonic acid)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(4-(4-dimethylaminophenylazo)benzoic acid)-Arg
Arg-Glu(5-[(2-aminoethyl)amino]-naphthalene-1-sulfonic acid)-Glu-Val-Asn-Leu + Asp-Ala-Glu-Phe-Lys(4-(4-dimethylaminophenylazo)benzoic acid)-Arg
show the reaction diagram
-
i.e. FS-1, cleavage occurs at Leu-Asp bond
-
-
?
Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(Dabcyl)-Arg + H2O
?
show the reaction diagram
-
-
-
-
?
basigin + H2O
?
show the reaction diagram
-
-
-
-
?
beta subunit of voltage-gated sodium channel + H2O
?
show the reaction diagram
-
-
-
-
?
beta-amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
beta-amyloid precursor protein + H2O
fragments of beta-amyloid precursor protein
show the reaction diagram
beta-amyloid precursor protein APP + H2O
beta-amyloid protein + beta-amyloid precursor protein pre-peptide
show the reaction diagram
beta-secretase 1 + H2O
?
show the reaction diagram
-
-
-
-
?
beta2 subunit of voltage-gated sodium channel + H2O
?
show the reaction diagram
biotin-GLTNIKTEEISEISYEVEFR-C + H2O
?
show the reaction diagram
-
-
-
-
?
biotin-KTEEISEVNFEVEFR + H2O
biotin-KTEEISEVNF + EVEFR
show the reaction diagram
BMP and activin membrane-bound inhibitor homolog + H2O
?
show the reaction diagram
-
-
-
-
?
cache domain containing 1 + H2O
?
show the reaction diagram
-
-
-
-
?
carboxypeptidase D + H2O
?
show the reaction diagram
-
-
-
-
?
casein-FITC + H2O
?
show the reaction diagram
-
-
-
-
?
cation-independent mannose-6-phosphate receptor + H2O
?
show the reaction diagram
-
-
-
-
?
CD166 antigen + H2O
?
show the reaction diagram
-
-
-
-
?
CD276 antigen + H2O
?
show the reaction diagram
-
-
-
-
?
CD44 + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate proteoglycan 4 + H2O
?
show the reaction diagram
-
-
-
-
?
contactin-1 + H2O
?
show the reaction diagram
-
-
-
-
?
contactin-2 + H2O
?
show the reaction diagram
-
substrate is a GPI-anchored cell adhesion molecule
mouse and human contactin-2 are physiological substrates for BACE1. BACE1-mediated contactin-2 cleavage tightly regulates the surface expression of contactin-2 in neuronal cells
-
?
cysteine-rich motor neuron 1 protein + H2O
?
show the reaction diagram
-
-
-
-
?
DABCYL-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-EDANS + H2O
?
show the reaction diagram
desmoglein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
disintegrin and metalloproteinase domain-containing protein 10 + H2O
?
show the reaction diagram
-
-
-
-
?
E-cadherin + H2O
?
show the reaction diagram
-
-
-
-
?
EEISEVKMDAEFRG + H2O
EEISEVKM + DAEFRG
show the reaction diagram
-
-
-
-
?
EEISEVNLDAEFRG + H2O
EEISEVNL + DAEFRG
show the reaction diagram
-
-
-
-
?
ephrin type-A receptor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin type-A receptor 4 + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin type-A receptor 7 + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin-A5 + H2O
?
show the reaction diagram
-
-
-
-
?
ErbB4 + H2O
?
show the reaction diagram
-
-
-
-
?
glypican-3 + H2O
?
show the reaction diagram
-
-
-
-
?
Golgi apparatus protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
Golgi phosphoprotein 4 + H2O
?
show the reaction diagram
-
-
-
-
?
H-RE(EDANS)EVNLDAEFK(dabcyl)R-OH + H2O
?
show the reaction diagram
-
-
-
-
?
hepatocyte growth factor receptor + H2O
?
show the reaction diagram
-
-
-
-
?
HLA class I histocompatibility antigen (combined) + H2O
?
show the reaction diagram
-
-
-
-
?
HTARWHLRAQDLHERSAAQLSLSS + H2O
?
show the reaction diagram
-
-
-
-
?
interleukin-6 receptor beta chain + H2O
?
show the reaction diagram
-
-
-
-
?
Jagged-1 + H2O
?
show the reaction diagram
-
-
-
-
?
Klotho protein + H2O
?
show the reaction diagram
-
-
-
-
?
Kunitz-type protease inhibitor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
leucin-rich repeats and immunoglobulin-like domains protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
leucin-rich repeats and immunoglobulin-like domains protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
leucin-rich repeats and immunoglobulin-like domains protein 3 + H2O
?
show the reaction diagram
-
-
-
-
?
leucine-rich repeat-containing protein 33 + H2O
?
show the reaction diagram
-
-
-
-
?
low density lipoprotein receptor-related protein + H2O
?
show the reaction diagram
-
-
-
-
?
low-density lipoprotein receptor-related protein 11 + H2O
?
show the reaction diagram
-
-
-
-
?
low-density lipoprotein receptor-related protein 4 + H2O
?
show the reaction diagram
-
-
-
-
?
M-2420 peptide + H2O
MCA-Ser-Glu-Val-Asn-Leu + Asp-Ala-Glu-Phe-(N6-dinitrophenylacetyl)Lys-amide
show the reaction diagram
-
cleavage occurs between Leu and Asp
-
-
?
Mca-SEVNLDAEFRK(2,4-dinitrophenyl)RR-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
membrane-bound prostaglandin E2 synthase-2 + H2O
?
show the reaction diagram
-
BACE-1 is involved in the cleavage of membrane-bound prostaglandin E2 synthase-2 in its N-terminal portion, which, in turn, enhances the generation of prostaglandin E2
-
-
?
N-cadherin + H2O
?
show the reaction diagram
-
-
-
-
?
neogenin + H2O
?
show the reaction diagram
-
-
-
-
?
netrin receptor UNC5C + H2O
?
show the reaction diagram
-
-
-
-
?
neuronal cell adhesion molecule 1 + H2O
?
show the reaction diagram
-
-
-
-
?
neuronal cell adhesion molecule L1 + H2O
?
show the reaction diagram
-
-
-
-
?
Notch + H2O
Notch intracellular domain + ?
show the reaction diagram
-
-
-
-
?
Notch protein + H2O
?
show the reaction diagram
-
-
-
-
?
Notch-1 + H2O
?
show the reaction diagram
-
-
-
-
?
oxidized insulin B chain + H2O
?
show the reaction diagram
-
-
-
-
?
panvera peptide + H2O
?
show the reaction diagram
-
-
-
-
?
peptidyl-glycine alpha-amidating monooxygenase + H2O
?
show the reaction diagram
-
-
-
-
?
plexin domain-containing protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
podocalyxin-like protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
poliovirus receptor type I + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin 21 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin 7 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma A11 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma A5 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma A8 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma C3 + H2O
?
show the reaction diagram
-
-
-
-
?
protogenin + H2O
?
show the reaction diagram
-
-
-
-
?
RE(EDANS)EVKMDAEFK(Dabcyl)R-NH2 + H2O
?
show the reaction diagram
-
substrate derived from amyloid beta positions -4 to 4, wild-type, internally fluorescent quenched. Very poor substrate
-
-
?
RE(EDANS)EVNLDAEFK(Dabcyl)R-NH2 + H2O
?
show the reaction diagram
-
substrate derived from amyloid beta positions -4 to 4, Swedish mutation, internally fluorescent quenched
-
-
?
receptor protein tyrosine kinase variant EPHB4V1 + H2O
?
show the reaction diagram
-
-
-
-
?
receptor-type tyrosin-protein phosphatase S + H2O
?
show the reaction diagram
-
-
-
-
?
Rh-EVNLDAEFK-quencher + H2O
?
show the reaction diagram
-
-
-
-
?
rhodamine-EVNLDAEFK-DABCYL + H2O
?
show the reaction diagram
-
-
-
-
?
rhodamine-EVNLDAEFK-Quencher
?
show the reaction diagram
-
FRET oligopeptide substrate
-
-
?
rhodamine-EVNLDAEFK-quencher + H2O
?
show the reaction diagram
rhodamine-EVNLDAEFK-quencher + H2O
rhodamine-EVNL + DAEFK-quencher
show the reaction diagram
-
-
-
-
?
roundabout homolog 1 + H2O
?
show the reaction diagram
-
-
-
-
?
roundabout homolog 2 + H2O
?
show the reaction diagram
-
-
-
-
?
seizure 6-like protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-4B + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-4C + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-6A + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-6D + H2O
?
show the reaction diagram
-
-
-
-
?
SEVKMDAEFR + H2O
SEVKM + DAEFR
show the reaction diagram
-
-
-
-
?
SEVKMDAEFRHDSGYEK-biotin + H2O
?
show the reaction diagram
-
-
-
-
?
SEVNLDAEFR + H2O
SEVNL + DAEFR
show the reaction diagram
-
-
-
-
?
SEVNLDAEFRHDSGYEK-biotin + H2O
?
show the reaction diagram
-
-
-
-
?
sidekick-1 + H2O
?
show the reaction diagram
-
-
-
-
?
sidekick-2 + H2O
?
show the reaction diagram
-
-
-
-
?
sortilin type I + H2O
?
show the reaction diagram
-
-
-
-
?
sortilin-related receptor type I + H2O
?
show the reaction diagram
-
-
-
-
?
ST6Gal I + H2O
?
show the reaction diagram
-
i.e. membrane-bound alpha2,6-sialyltransferase, cleavage occurs between Leu37 and Gln38
-
-
?
Swedish mutation of amyloid precursor protein + H2O
fragments of Swedish mutation of amyloid precursor protein
show the reaction diagram
-
-
-
-
?
Swedish variant of amyloid precursor protein + H2O
?
show the reaction diagram
syndecan-4 + H2O
?
show the reaction diagram
-
-
-
-
?
T-cell immunomodulatory protein + H2O
?
show the reaction diagram
-
-
-
-
?
toll-like receptor 9 + H2O
?
show the reaction diagram
-
-
-
-
?
trans-Golgi network integral membrane protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
transmembrane protein 132A + H2O
?
show the reaction diagram
-
-
-
-
?
tumor necrosis factor receptor superfamily member 21 + H2O
?
show the reaction diagram
-
-
-
-
?
ubiquitin + H2O
?
show the reaction diagram
-
-
-
-
?
vesicular integral-membrane protein VIP36 + H2O
?
show the reaction diagram
-
-
-
-
?
Z-Val-Asn-Leu-7-amido-4-methylcoumarin + H2O
Z-Val-Asn-Leu + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
amyloid -like PROTEIN 2 + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid beta-precursor protein + H2O
?
show the reaction diagram
amyloid pbeta A4 protein + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
?
show the reaction diagram
amyloid precursor protein + H2O
amyloid beta protein 40 + amyloid beta protein 42
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
beta-amyloid peptide 40 + beta-amyloid peptide 42
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
C-terminal fragment + soluble N-terminal fragment APPbeta
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
C-terminal fragment C99 of amyloid precursor protein + ?
show the reaction diagram
-
-
-
-
?
amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
amyloid precursor protein + H2O
neurotrophic soluble amyloid precursor protein + ?
show the reaction diagram
-
-
-
-
?
amyloid precursor protein-DELTANL + H2O
?
show the reaction diagram
-
the Swedish familial mutation in APP (DELTANL) enhances beta-secretase cleavage
-
-
?
amyloid-beta precursor protein + H2O
amyloid-beta protein 40 + amyloid-beta protein 42
show the reaction diagram
-
-
-
-
?
amyloid-beta precursor protein + H2O
fragments of amyloid-beta precursor protein
show the reaction diagram
amyloid-like protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
basigin + H2O
?
show the reaction diagram
-
-
-
-
?
beta subunit of voltage-gated sodium channel + H2O
?
show the reaction diagram
-
-
-
-
?
beta-amyloid precursor protein + H2O
fragments of amyloid precursor protein
show the reaction diagram
beta-amyloid precursor protein + H2O
fragments of beta-amyloid precursor protein
show the reaction diagram
beta-secretase 1 + H2O
?
show the reaction diagram
-
-
-
-
?
beta2 subunit of voltage-gated sodium channel + H2O
?
show the reaction diagram
BMP and activin membrane-bound inhibitor homolog + H2O
?
show the reaction diagram
-
-
-
-
?
cache domain containing 1 + H2O
?
show the reaction diagram
-
-
-
-
?
carboxypeptidase D + H2O
?
show the reaction diagram
-
-
-
-
?
cation-independent mannose-6-phosphate receptor + H2O
?
show the reaction diagram
-
-
-
-
?
CD166 antigen + H2O
?
show the reaction diagram
-
-
-
-
?
CD276 antigen + H2O
?
show the reaction diagram
-
-
-
-
?
CD44 + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate proteoglycan 4 + H2O
?
show the reaction diagram
-
-
-
-
?
contactin-1 + H2O
?
show the reaction diagram
-
-
-
-
?
cysteine-rich motor neuron 1 protein + H2O
?
show the reaction diagram
-
-
-
-
?
desmoglein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
disintegrin and metalloproteinase domain-containing protein 10 + H2O
?
show the reaction diagram
-
-
-
-
?
E-cadherin + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin type-A receptor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin type-A receptor 4 + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin type-A receptor 7 + H2O
?
show the reaction diagram
-
-
-
-
?
ephrin-A5 + H2O
?
show the reaction diagram
-
-
-
-
?
ErbB4 + H2O
?
show the reaction diagram
-
-
-
-
?
glypican-3 + H2O
?
show the reaction diagram
-
-
-
-
?
Golgi apparatus protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
Golgi phosphoprotein 4 + H2O
?
show the reaction diagram
-
-
-
-
?
hepatocyte growth factor receptor + H2O
?
show the reaction diagram
-
-
-
-
?
HLA class I histocompatibility antigen (combined) + H2O
?
show the reaction diagram
-
-
-
-
?
interleukin-6 receptor beta chain + H2O
?
show the reaction diagram
-
-
-
-
?
Jagged-1 + H2O
?
show the reaction diagram
-
-
-
-
?
Klotho protein + H2O
?
show the reaction diagram
-
-
-
-
?
Kunitz-type protease inhibitor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
leucin-rich repeats and immunoglobulin-like domains protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
leucin-rich repeats and immunoglobulin-like domains protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
leucin-rich repeats and immunoglobulin-like domains protein 3 + H2O
?
show the reaction diagram
-
-
-
-
?
leucine-rich repeat-containing protein 33 + H2O
?
show the reaction diagram
-
-
-
-
?
low-density lipoprotein receptor-related protein 11 + H2O
?
show the reaction diagram
-
-
-
-
?
low-density lipoprotein receptor-related protein 4 + H2O
?
show the reaction diagram
-
-
-
-
?
membrane-bound prostaglandin E2 synthase-2 + H2O
?
show the reaction diagram
-
BACE-1 is involved in the cleavage of membrane-bound prostaglandin E2 synthase-2 in its N-terminal portion, which, in turn, enhances the generation of prostaglandin E2
-
-
?
N-cadherin + H2O
?
show the reaction diagram
-
-
-
-
?
neogenin + H2O
?
show the reaction diagram
-
-
-
-
?
netrin receptor UNC5C + H2O
?
show the reaction diagram
-
-
-
-
?
neuronal cell adhesion molecule 1 + H2O
?
show the reaction diagram
-
-
-
-
?
neuronal cell adhesion molecule L1 + H2O
?
show the reaction diagram
-
-
-
-
?
Notch + H2O
Notch intracellular domain + ?
show the reaction diagram
-
-
-
-
?
Notch protein + H2O
?
show the reaction diagram
-
-
-
-
?
Notch-1 + H2O
?
show the reaction diagram
-
-
-
-
?
peptidyl-glycine alpha-amidating monooxygenase + H2O
?
show the reaction diagram
-
-
-
-
?
plexin domain-containing protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
podocalyxin-like protein 1 + H2O
?
show the reaction diagram
-
-
-
-
?
poliovirus receptor type I + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin 21 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin 7 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma A11 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma A5 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma A8 + H2O
?
show the reaction diagram
-
-
-
-
?
protocadherin gamma C3 + H2O
?
show the reaction diagram
-
-
-
-
?
protogenin + H2O
?
show the reaction diagram
-
-
-
-
?
receptor protein tyrosine kinase variant EPHB4V1 + H2O
?
show the reaction diagram
-
-
-
-
?
receptor-type tyrosin-protein phosphatase S + H2O
?
show the reaction diagram
-
-
-
-
?
rhodamine-EVNLDAEFK-quencher + H2O
?
show the reaction diagram
-
-
-
-
?
roundabout homolog 1 + H2O
?
show the reaction diagram
-
-
-
-
?
roundabout homolog 2 + H2O
?
show the reaction diagram
-
-
-
-
?
seizure 6-like protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-4B + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-4C + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-6A + H2O
?
show the reaction diagram
-
-
-
-
?
semaphoring-6D + H2O
?
show the reaction diagram
-
-
-
-
?
sidekick-1 + H2O
?
show the reaction diagram
-
-
-
-
?
sidekick-2 + H2O
?
show the reaction diagram
-
-
-
-
?
sortilin type I + H2O
?
show the reaction diagram
-
-
-
-
?
sortilin-related receptor type I + H2O
?
show the reaction diagram
-
-
-
-
?
Swedish mutation of amyloid precursor protein + H2O
fragments of Swedish mutation of amyloid precursor protein
show the reaction diagram
-
-
-
-
?
syndecan-4 + H2O
?
show the reaction diagram
-
-
-
-
?
T-cell immunomodulatory protein + H2O
?
show the reaction diagram
-
-
-
-
?
toll-like receptor 9 + H2O
?
show the reaction diagram
-
-
-
-
?
trans-Golgi network integral membrane protein 2 + H2O
?
show the reaction diagram
-
-
-
-
?
transmembrane protein 132A + H2O
?
show the reaction diagram
-
-
-
-
?
tumor necrosis factor receptor superfamily member 21 + H2O
?
show the reaction diagram
-
-
-
-
?
vesicular integral-membrane protein VIP36 + H2O
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Cu
-
BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper
Cu2+
-
involvement of aspartic proteinase BACE1 in copper homoeostasis shown, key role of the central of three cysteines (amino acid 482 in 501-amino-acid isoform of BACE1) in metal binding indicated
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(+)-byakangelicin
-
-
(+)-byakangelicol
-
-
(+)-oxypeucedanin
-
-
(-)-gallocatechin gallate
-
less potent inhibitor
(13S)-15-amino-10,13-dicyclohexyl-19-fluoro-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-11-one
-
-
(13S)-15-amino-10,13-dicyclohexyl-19-methoxy-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-11-one
-
-
(13S)-15-amino-10,13-dicyclohexyl-2-oxa-10,14,16,19-tetraazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-11-one
-
-
(14S)-16-amino-10,14-dicyclohexyl-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
potent inhibitor
(14S)-16-amino-10-cyclohexyl-14-(propan-2-yl)-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
-
(14S)-16-amino-14-(propan-2-yl)-10-(tetrahydro-2H-pyran-4-yl)-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
-
(14S)-16-amino-14-cyclohexyl-10-(tetrahydro-2H-pyran-4-yl)-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
-
(15R)-17-amino-11,15-dicyclohexyl-2-oxa-11,16,18-triazatetracyclo[14.5.3.1(3,7).0(19,23)]pentacosa-1(21),3(25),4,6,17,19,22-heptaen-12-one
-
-
(15S)-17-amino-11,15-dicyclohexyl-2-oxa-11,16,18-triazatetracyclo[14.5.3.1(3,7).0(19,23)]pentacosa-1(21),3(25),4,6,17,19,22-heptaen-12-one
-
-
(1R,3S)-3-[(1S)-1-(acetylamino)-2-methylpropyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-3-[(1S)-1-(acetylamino)-3-methylbutyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
11% inhibition at 0.01 mM
(1R,3S)-3-[(1S)-1-(acetylamino)butyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
15% inhibition at 0.01 mM
(1R,3S)-3-[(1S)-1-(acetylamino)ethyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
8% inhibition at 0.01 mM
(1R,3S)-3-[(1S)-1-(acetylamino)propyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
17% inhibition at 0.01 mM
(1R,3S)-3-[1-(acetylamino)-3-methylbutyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
42% inhibition at 0.01 mM
(1R,3S)-3-[1-(acetylamino)butyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
80% inhibition at 0.01 mM
(1R,3S)-3-[1-(acetylamino)cyclopentyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-3-[1-(acetylamino)ethyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
14% inhibition at 0.01 mM
(1R,3S)-3-[1-(acetylamino)propyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
24% inhibition at 0.01 mM
(1R,3S)-3-[2-(acetylamino)propan-2-yl]-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-3-[2-(acetylamino)propan-2-yl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(2-oxopiperidin-1-yl)propan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(2-oxopyrrolidin-1-yl)propan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(propanoylamino)propan-2-yl]cyclohexanecarboxamide
-
-
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-[methyl(propanoyl)amino]propan-2-yl]cyclohexanecarboxamide
-
-
(1S,2R)-N-[1-benzyl-2-hydroxy-3-(S)-[(1-benzylpiperidin-4-yl)amino]-propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(R)-1-phenylethyl]isophthalamide
-
-
(1S,2R)-N-[1-benzyl-2-hydroxy-3-(S)-[2-(1-benzylpiperidin-4-yl)ethylamino]-propyl]-5-[methyl(methylsulfonyl)-amino]-N'-[(R)-1-(4-fluorophenyl)ethyl]isophthalamide
-
-
(1S,2R)-N-[1-benzyl-2-hydroxy-3-(S)-[2-(1-benzylpiperidin-4-yl)ethylamino]-propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(R)-1-phenylethyl]isophthalamide
-
dual inhibitor of both beta-secretase and acetylcholinesterase, good inhibitory effects on amyloid beta production of amyloid precursor protein transfected HEK293 cells
(1S,2R)-N-{1-benzyl-2-hydroxy-3-(S)-[2-(1-benzylpiperidin-4-yl)ethylamino]-propyl}-5-[methyl(methylsulfonyl)amino]-N'-[(R)-1-phenylethyl]isophthalamide
-
dual inhibitor of both beta-secretase and acetylcholinesterase. Intracerebroventricular injection of into amyloid precursor protein transgenic mice causes a 29% reduction of amyloid beta1-40 production
(2R,4S)-N-butyl-4-hydroxy-2-methyl-4-[(2S,5S,7R)-1,2,7-trimethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl]butanamide
-
56fold selectivity for beta-secretase over cathepsin D
(2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7-dimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl]-4-hydroxy-2-methylbutanamide
-
-
(2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7-dimethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl]-4-hydroxy-2-methylbutanamide
-
-
(2R,4S,5S)-N-benzyl-4-hydroxy-2,7-dimethyl-5-[(N-[(2Z)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]-L-seryl)amino]octanamide
-
16.45% inhibition at 0.01 mg/ml
(2R,4S,5S)-N-benzyl-4-hydroxy-5-([N-[(4-methoxyphenyl)acetyl]-L-seryl]amino)-2,7-dimethyloctanamide
-
25.09% inhibition at 0.01 mg/ml
(2S)-2-((3R)-3-acetamido-3-isobutyl-2-oxo-1-pyrrolidinyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-2-(1,2,3,4-tetrahydro-3-isoquinolinyl)ethyl)-4-phenylbutanamide
-
crystallization data, EC50 value for HEK293 cells 10 nM
(2S)-2-((S)-3-acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1S,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R)-5-(propylsulfonyl)pyrrolidin-2-yl)propan-2-yl)-4-phenylbutanamide
(2S,5S,8S,11S,14S)-14-amino-5-benzyl-8-(cyclohexylmethyl)-16-(5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-2-hydroxy-11-(1-methylethyl)-4,7,10,13,16-pentaoxo-N-[3-(2H-tetrazol-5-yl)phenyl]-3,6,9,12-tetraazahexadecan-1-amide
-
i.e. KMI-574, 100% and 97% inhibition at 2 microM and 0.2 microM, respectively, 84% inhibition of beta-secretase BACE1 in cultured cell-based assay at 100 microM
(3S,14R,16S)-16-[(1R)-1-hydroxy-2-([3-(1-methylethyl)benzyl]amino)ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione
(3S,14R,16S)-16-[(1S)-2-[[(1R)-3,3-dimethyl-7-(1-methylethyl)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]-1-hydroxyethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione
(3S,5R)-3-(4-amino-3-fluoro-5-[[(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl]oxy]benzyl)-5-[(3-tert-butylbenzyl)amino]-4-hydroxytetrahydro-2H-thiopyranium-1-olate
-
highly potent, selective inhibitors with improved cellular activity. Sufficient central nervous system exposure can be achieved with a single oral dose of 60 micromol/kg to effect significant reduction in brain amyloid beta in APP51/16 transgenic mice
(4aR,6R,8aS)-8a-(2,4-difluorophenyl)-6-(fluoromethyl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine
-
upon oral administration, inhibitor exhibits robust brain availability and is efficacious in lowering central amyloid beta levels in mouse and dog. Chronic treatment in aged PS1/APP mice effects a decrease in the number and size of amyloid-beta-derived plaques. Evaluation of the inhibitor in a 2-week exploratory toxicology study exhibits no accumulation of autofluorescent material in retinal pigment epithelium or histology findings in the eye
(4aS,4'S,10aR)-8-(2-fluoropyridin-3-yl)-4a-methyl-3,4,4a,10a-tetrahydro-2H,5'H-spiro[pyrano[3,2-b]chromene-10,4'-thiazol]-2'-amine
-
compound demonstrates a 69% reduction in rat cerebrospinal fluid amyloid beta1?40 at 60 mg/kg
(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]cyclopropyl]amino)ethyl]-19-(2-oxopyrrolidin-1-yl)-11,16-dioxa-3-azatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]cyclopropyl]amino)ethyl]-19-(methoxymethyl)-11,16-dioxa-3,18-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]cyclopropyl]amino)ethyl]-19-methyl-11,16-dioxa-3,18-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]ethyl]amino)ethyl]-19-methyl-11,16-dioxa-3,18-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-([2-[3-(propan-2-yl)phenyl]propan-2-yl]amino)ethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-19-methyl-11,16-dioxa-3,18-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-19-methyl-11-oxa-3,16,18-triazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)-2,2,2-trifluoroethyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)-2-fluoroethyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)-2-methoxyethyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)cyclobutyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(4S)-4-[(1R)-2-[[1-(3-tert-butylphenyl)cyclopentyl]amino]-1-hydroxyethyl]-19-(methoxymethyl)-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-2-one
-
-
(5S)-2-amino-5-(2',4'-difluorobiphenyl-3-yl)-3-methyl-5-(pyridin-4-yl)-3,5-dihydro-4H-imidazol-4-one
-
5fold selectivity for BACE2 over BACE1, 27fold selectivity for BACE2 over cathepsin D
(5S)-2-amino-5-[3-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
(6R)-2,6-anhydro-5-O-[(E)-2-(4-hydroxyphenyl)ethenyl]-6-[2-[(2R)-2-hydroxypropyl]-7-methoxy-5-methyl-4-oxo-4H-chromen-8-yl]-L-glucitol
-
inhibitor isolated from Aloe vera and Aloe nobilis. Inhibition of amyloid beta1-42 production by 7.4% in B103 neuroblastoma cells at 30 ppm
(6R)-2,6-anhydro-6-[7-methoxy-5-methyl-4-oxo-2-[(1E)-prop-1-en-1-yl]-4H-chromen-8-yl]-L-glucitol
-
inhibitor isolated from Aloe vera and Aloe nobilis. Inhibition of amyloid beta1-42 production by 12.3% in B103 neuroblastoma cells at 30 ppm
(7S,12Z)-N-[(2S,4R)-2-hydroxy-4-methyl-5-[[(1S)-2-methyl-1-(phenylcarbamoyl)propyl]amino]-1-(2-methylpropyl)-5-oxopentyl]-4-(1-methylethyl)-2,5,9-trioxo-1-oxa-3,6,10-triazacyclohexadec-12-ene-7-carboxamide
-
-
(R)-3-(2-amino-6-(3-chloropyridin-2-yl)quinolin-3-yl)-N-(3,3-dimethylbutyl)-2-methylpropanamide
-
EC50 value for cell assay 80 nM
(R)-3-(2-amino-6-(3-methylpyridin-2-yl)quinolin-3-yl)-N-(3,3-dimethylbutyl)-2-methylpropanamide
-
EC50 value for cell assay 35 nM
(S)-3-(6,6-dimethyl-3,6-dihydro-2H-pyran-4-yl)-7-(2-fluoropyridin-3-yl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine
-
inhibitor shows good BACE1 functional potency, permeability, intrinsic stability, and P-glycoprotein efflux ratios
(S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5H-spiro[chromeno[2,3-b]pyridine-5,4-oxazol]-2-amine
-
i.e. AMG-8718.compound exhibits a balanced profile of BACE1 potency, hERG binding affinity, and P-glycoprotein recognition. Compound produces robust and sustained reductions of cerebrospinal fluid and brain amyloid beta levels in a rat pharmacodynamic model
1,1'-piperazine-1,4-diylbis[3-(3,6-dichloro-9H-carbazol-9-yl)propan-2-ol]
-
inhibitor identified by in silico mulit-filter approaches. Calculated binding free energy of R,S-isomer -48 kcal/mol
1,1'-piperazine-1,4-diylbis[3-(9H-carbazol-9-yl)propan-2-ol]
-
inhibitor identified by in silico mulit-filter approaches. Calculated binding free energy of S,R-isomer -48.2 kcal/mol
1,3-bis(3,5-bis(trifluoromethyl)phenyl)urea
-
100% inhibition at 100 nM, 15% inhibition at 10 nM
1,5-anhydro-1-[7-hydroxy-2-[(2S)-2-hydroxypropyl]-5-methyl-4-oxo-4H-chromen-8-yl]hexitol
-
37.2% inhibition at 0.1 mM
1,5-anhydro-1-[7-hydroxy-5-methyl-4-oxo-2-(2-oxopropyl)-4H-chromen-8-yl]-2-O-[(E)-2-(4-hydroxyphenyl)ethenyl]hexitol
-
39.5% inhibition at 0.1 mM
1,5-anhydro-1-[7-methoxy-5-methyl-4-oxo-2-(2-oxopropyl)-4H-chromen-8-yl]hexitol
-
41.0% inhibition at 0.1 mM
1,5-anhydro-2-O-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-1-[7-hydroxy-5-methyl-4-oxo-2-(2-oxopropyl)-4H-chromen-8-yl]hexitol
-
36.4% inhibition at 0.1 mM
1,5-anhydro-2-O-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-1-[7-methoxy-5-methyl-4-oxo-2-(2-oxopropyl)-4H-chromen-8-yl]hexitol
-
48.7% inhibition at 0.1 mM
1-(2-chlorobenzyl)-4-(4-(dibenzo[b,d]furan-1-yl)benzyl)-1H-imidazol-2-amine
-
0.005 mM, 37.8% inhibition. Inhibitor is predicted to be able to cross the blood-brain barrier
1-(3,5-bis(trifluoromethyl)-phenyl)-3-(3,5-dimethylphenyl)urea
-
80% inhibition at 100 nM
1-(4-fluorobenzyl)-4-((30,50-dimethoxybiphenyl-4-yl)methyl)-1H-imidazol-2-amine
-
0.005 mM, 40% inhibition. Inhibitor is predicted to be able to cross the blood-brain barrier
1-[ (3-benzoylamino-phenylcarbamoyl)-methyl]-pyridinium chloride
-
51% inhibition at 0.05 mM
1-[(3-benzoylamino-phenylcarbamoyl)-methyl]-3-carbamoyl-pyridiniumchloride
-
54% inhibition at 0.05 mM
1-[(3-benzoylamino-phenylcarbamoyl)-methyl]-3-phenethylcarbamoyl-pyridinium chloride
-
55% inhibition at 0.05 mM
1-[(3-m-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
-
61% inhibition at 0.05 mM
1-[(3-p-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
-
42% inhibition at 0.05 mM
1-[(E)-[(4-methylquinazolin-2-yl)amino][(phenylcarbamoyl)amino]methylidene]-3-phenylurea
-
complete inhibition at 0.1 mM
1-[[3-(4-chloro-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-3-phenethylcarbamoyl-pyridinium chloride
-
78% inhibition at 0.05 mM
1-[[3-(4-chloro-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
complete inhibition at 0.05 mM
1-[[3-(4-methoxy-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-3-phenethylcarbamoyl-pyridinium chloride
-
44% inhibition at 0.05 mM
1-[[3-(4-methoxy-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
complete inhibition at 0.05 mM
1-[[3-(4-methoxy-phenylsulfamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
50% inhibition at 0.05 mM
1-[[3-(4-methyl-benzoylamino)-phenylcarbamoyl]-methyl]-3-phenethylcarbamoyl-pyridinium chloride
-
complete inhibition at 0.05 mM
1-[[3-(4-methyl-benzoylamino)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
-
11-oxo-N-(pyridin-4-yl)-10,11-dihydro-5H-dibenzo[b,e][1,4]-diazepine-3-carboxamide
-
-
16-amino-11-cyclohexyl-2-oxa-11,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-12-one
-
-
1[[3-(4-methyl-benzoylamino)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
68% inhibition at 0.05 mM
2'-O-coumaroyl-(S)-aloesinol
-
51.9% inhibition at 0.1 mM
2'-O-[p-methoxy-(E)-cinnamoyl]-(S)-aloesinol
-
34.1% inhibition at 0.1 mM
2,3-dihydro-6-methylginkgetin
-
isolated from from Cephalotaxus harringtonia var. fastigiata
2,3-dihydroamentoflavone
-
a 2,3-dihydroamentoflavone from Cycas revoluta
2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
-
i.e. norartocarpetin, prenylated flavone from the stem bark of Morus lhou, noncompetitive
2-(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-6-methoxy-1Hbenzo[d]imidazole
-
inhibitor of BACE1, EC 3.4.23.46. 150fold more effective on BACE1 than BACE2
2-amino-3,4-dihydroquinazoline
-
-
2-amino-3-ethyl-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-(2-methylpyridin-4-yl)-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-(2-methylpyridin-4-yl)-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-(pyridin-4-yl)-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
exhibits modest selectivity (about 8fold) against BACE2
2-amino-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-5-[3-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-phenyl-5-(pyridin-4-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-phenyl-5-(tricyclo[3.3.1.13,7]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-[2-(propan-2-yl)pyridin-4-yl]-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-3-methyl-5-[2-methyl-6-(propan-2-yl)pyridin-4-yl]-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
24% inhibition at 0.0125 mM
2-amino-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(1,3-benzodioxol-5-yl)-3-methyl-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methyl-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(2,3-dihydro-1-benzofuran-5-yl)-3-methyl-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(2,6-diethylpyridin-4-yl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(2,6-dimethylpyridin-4-yl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(2-ethyl-6-methylpyridin-4-yl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
28% inhibition at 0.0125 mM
2-amino-5-(2-ethylpyridin-4-yl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3,4-dimethoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3-butoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3-chlorophenyl)-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3-ethoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3-methoxy-4-methylphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3-methoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(3-methoxyphenyl)-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(4-chlorophenyl)-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(4-ethyl-3-methoxyphenyl)-3-methyl-5-(tricyclo[3.3.1.1(3,7)]dec-1-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(4-methoxy-3-methylphenyl)-3-methyl-5-(6-methylbiphenyl-3-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(4-methoxy-3-methylphenyl)-3-methyl-5-[3-(pyridin-3-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(4-methoxy-3-methylphenyl)-3-methyl-5-[3-(pyrimidin-5-yl)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(4-methoxyphenyl)-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-3-methyl-5-(pyridin-4-yl)-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3,4-dimethoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3-butoxy-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3-chloro-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3-cyclopentyl-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3-ethoxy-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3-ethoxy-4-propoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(3-fluoro-4-methoxyphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-[4-methoxy-3-(propan-2-yloxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-(biphenyl-3-yl)-5-[4-methoxy-3-(trifluoromethyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[2-fluoro-3-(pyrimidin-5-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[3-(2-fluoropyridin-3-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[3-(2-methoxypyridin-3-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[3-(6-fluoropyridin-3-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[3-(6-methoxypyridin-3-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[3-fluoro-5-(pyrimidin-5-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[4-fluoro-3-(2-fluoropyridin-3-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[4-fluoro-3-(pyrimidin-5-yl)phenyl]-3-methyl-5-[4-(trifluoromethoxy)phenyl]-3,5-dihydro-4H-imidazol-4-one
-
-
2-amino-5-[4-fluoro-3-(pyrimidin-5-yl)phenyl]-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
-
; aminohydantoin inhibitor, shows comparable activity in a cell-based assay, and demonstrates more than 100fold selectivity for the other structurally related aspartyl proteases BACE2, cathepsinD, renin, and pepsin
2-deoxy-4-O-beta-D-glucopyranuronosyl-6-O-sulfo-2-(sulfoamino)-beta-D-glucopyranose
-
IC50: 0.000053 mg/ml
2-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)amino]-2-oxoethyl [(4,6-diphenylpyrimidin-2-yl)sulfanyl]acetate
-
75% inhibition at 0.1 mM
2-[(3-cyano-4,6-diphenylpyridin-2-yl)sulfanyl]-N-(3-nitrophenyl)acetamide
-
complete inhibition at 0.1 mM
2-[(4-methyl-5-[2-[(4-methylphenyl)amino]-2-oxoethyl]-4H-1,2,4-triazol-3-yl)sulfanyl]-N-(4-phenyl-1,3-thiazol-2-yl)acetamide
-
83% inhibition at 0.1 mM
2-[(6-[[4,6-di(piperidin-1-yl)-1,3,5-triazin-2-yl]amino]-1,3-benzothiazol-2-yl)sulfanyl]-N-(2-fluorophenyl)acetamide
-
90% inhibition at 0.1 mM
2-[[(1S,2S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]carbamoyl]-6-[[(4S)-4-phenyl-1,3-oxazolidin-3-yl]carbonyl]pyridin-4-yl methanesulfonate
-
i.e. KMI-1036, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
2-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pentyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]amino]ethanol
-
-
2-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pentyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]oxy]ethanol
-
1.7% inhibition at 0.0125 mM
2-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pyrimidin-5-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]amino]ethanol
-
8.46% inhibition at 0.0125 mM
2-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pyrimidin-5-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]oxy]ethanol
-
5.43% inhibition at 0.0125 mM
2-[[3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-yl]sulfanyl]-N-(tricyclo[3.3.1.1(3,7)]dec-1-yl)acetamide
-
45% inhibition at 0.1 mM
2-[[3-cyano-6-(4-fluorophenyl)-4-phenylpyridin-2-yl]sulfanyl]-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide
-
80% inhibition at 0.1 mM
2-[[4-(4-chlorophenyl)-3-cyano-6-(4-methoxyphenyl)pyridin-2-yl]sulfanyl]-N-(naphthalen-2-yl)-N-phenylacetamide
-
68% inhibition at 0.1 mM
2-[[4-benzyl-5-(1H-indol-3-ylmethyl)-4H-1,2,4-triazol-3-yl]sulfanyl]-1-(1H-indol-3-yl)ethanone
-
75% inhibition at 0.1 mM
3-(3H-imidazo[4,5-c]pyridin-2-yl)-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one
-
-
3-(5-((7aR)-6-(5-fluoropyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile
-
orally active, brain penetrant inhibitor that reduces amyloid beta40 in the plasma, cerebrospinal fluid, and cortex of rats in a dose-dependent manner
3-(5-(4-fluorophenyl)-1H-imidazol-2-yl)-5H dibenzo[b,e][1,4]diazepin-11(10H)-one
-
-
3-(5-(pyridin-4-yl)-1H-imidazol-2-yl)-5H dibenzo[b,e][1,4]-diazepin-11(10H)-one
-
-
3-(6-(2-acetylphenyl)-2-aminoquinolin-3-yl)-N-(3,3-dimethylbutyl)-2-methylpropanamide
-
EC50 value for cell assay 11 nM
3-(6-fluoro-1H-benzo[d]imidazol-2-yl)-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one
-
-
3-(benzylsulfanyl)-6-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6,7-dihydro[1,2,4]triazino[5,6-d][3,1]benzoxazepine
-
48% inhibition at 0.1 mM
3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-N2-(3,3,3-trifluoropropanoyl)-D-alaninamide
-
-
3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-N2-(methoxyacetyl)-D-alaninamide
-
-
3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-N2-(pyridin-3-ylacetyl)-D-alaninamide
-
-
3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-N2-(pyridin-4-ylacetyl)-D-alaninamide
-
-
3-(butylsulfonyl)-N2-(3-cyanopropanoyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
-
-
3-(butylsulfonyl)-N2-(cyclopropylcarbonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
-
-
3-(cyclohexylsulfonyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]propanamide
-
-
3-(dibutylsulfamoyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]propanamide
-
-
3-(dipropylsulfamoyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]propanamide
-
-
3-(heptan-4-ylsulfonyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]propanamide
-
-
3-carbamoyl-1-[(3-m-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
-
44% inhibition at 0.05 mM
3-carbamoyl-1-[(3-p-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
-
69% inhibition at 0.05 mM
3-carbamoyl-1-[[3-(4-chloro-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
64% inhibition at 0.05 mM
3-carbamoyl-1-[[3-(4-methoxy-phenylcarbamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
complete inhibition at 0.05 mM
3-carbamoyl-1-[[3-(4-methoxy-phenylsulfamoyl)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
34% inhibition at 0.05 mM
3-carbamoyl-1-[[3-(4-methyl-benzoylamino)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
24% inhibition at 0.05 mM
3-carbamoyl-1-[[3-(toluene-4-sulfonylamino)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
4% inhibition at 0.05 mM
3-chloro-N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]benzamide
-
-
3-phenethylcarbamoyl-1-[(3-m-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
-
58% inhibition at 0.05 mM
3-phenethylcarbamoyl-1-[(3-p-tolylcarbamoyl-phenylcarbamoyl)-methyl]-pyridinium chloride
-
72% inhibition at 0.05 mM
3-phenethylcarbamoyl-1-[[3-(toluene-4-sulfonylamino)-phenylcarbamoyl]-methyl]-pyridinium chloride
-
36% inhibition at 0.05 mM
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-di-2H-tetrazol-5-ylphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-dicarboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3-carbamoylphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.0002 mM, 78.1% inhibition
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3-carboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(2H-tetrazol-5-yl)phenyl]amino)propyl]-L-leucinamide
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]amino)propyl]-L-leucinamide
-
0.0002 mM, 94.2% inhibition, IC50: 6.6 nM
3-[(2H-tetrazol-5-ylcarbonyl)amino]-L-alanyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]amino)propyl]-L-leucinamide
-
0.0002 mM, 97.2% inhibition, IC50: 6.4 nM
3-[(2H-tetrazol-5-ylcarbonyl)amino]alanyl-L-valyl-N-(1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl)leucinamide
-
-
3-[(2H-tetrazol-5-ylcarbonyl)amino]alanyl-L-valyl-N-[1-benzyl-3-[(3,5-di-2H-tetrazol-5-ylphenyl)amino]-2-hydroxy-3-oxopropyl]leucinamide
-
-
3-[2-amino-6-(phenylcarbonyl)quinazolin-3(4H)-yl]-N-cyclohexyl-N-methylpropanamide
-
-
3-[5-[(1R)-1-amino-1-methyl-2-phenylethyl]-1,3,4-oxadiazol-2-yl]-N-[1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]benzamide
-
-
3-[[(5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)carbonyl]amino]alanyl-L-valyl-N-[(1S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]phenylalaninamide
-
-
3-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pentyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]amino]propan-1-ol
-
-
3-[[2-amino-6-([2-(2-chlorophenyl)-5-[4-(pentyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-3-yl]oxy]propan-1-ol
-
47% inhibition at 0.0125 mM
4-(2-amino-6-phenoxyquinazolin-3(4H)-yl)-N,4-dicyclohexyl-N-methylbutanamide
-
-
4-(4-[1-[(6-aminopyridin-2-yl)methyl]-5-(2-chlorophenyl)-1H-pyrrol-2-yl]phenoxy)butanenitrile
-
-
4-(cyclohexylamino)-1-(4-fluorobenzyl)-8-[(2'-methylbiphenyl-4-yl)methyl]-1,3,8-triazaspiro[4.5]dec-3-en-2-one
-
-
4-(dipropylsulfamoyl)-N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]butanamide
-
-
4-bromo-N-[(4-bromophenyl)sulfonyl]-N-[1-(3,4-dichlorobenzyl)-1H-pyrazol-4-yl]benzenesulfonamide
-
50% inhibition at 0.1 mM
4-fluoro-1-(pyridin-4-yl)-1-[3-(pyrimidin-5-yl)phenyl]-1H-isoindol-3-amine
-
i.e. AZ2000. Inhibitor with improved brain disposition, reduces amyloid beta levels in both brain and periphery already after acute dosing. Mice heterozygous for BACE1, display a 62% reduction in plasma amyloid beta40 levels, whereas brain amyloid beta40 is only lowered by 11%
4-[1-(4-methoxyphenyl)-2-[4-(trifluoromethyl)phenyl]ethyl]-1-methyl-1H-imidazol-2-amine
-
-
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-(prop-2-en-1-yl)benzamide
-
6.2% inhibition at 0.0125 mM
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-(propan-2-yl)benzamide
-
6.58% inhibition at 0.0125 mM
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-butylbenzamide
-
45% inhibition at 0.0125 mM
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-cyclobutylbenzamide
-
38.4% inhibition at 0.0125 mM
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-cyclopropylbenzamide
-
10.6% inhibition at 0.0125 mM
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-ethylbenzamide
-
36% inhibition at 0.0125 mM
4-[1-[(6-aminopyridin-2-yl)methyl]-5-phenyl-1H-pyrrol-2-yl]-N-propylbenzamide
-
28% inhibition at 0.0125 mM
4-[2-(2-methoxy-5-nitrophenyl)-1-(4-methoxyphenyl)ethyl]-1-methyl-1H-imidazol-2-amine
-
-
4-[4-fluoro-5-methoxy-2-[4-(trifluoromethyl)phenyl]-2,3-dihydro-1H-inden-1-yl]-1-methyl-1H-imidazol-2-amine
-
highly active BACE-1 inhibitor
4-[5-methoxy-2-(2-methoxy-5-nitrophenyl)-2,3-dihydro-1H-inden-1-yl]-1-methyl-1H-imidazol-2-amine
-
-
4-[5-methoxy-2-[4-(trifluoromethyl)phenyl]-2,3-dihydro-1H-inden-1-yl]-1-methyl-1H-imidazol-2-amine
-
-
4-[8-benzyl-4-(cyclohexylamino)-2-oxo-1,3,8-triazaspiro[4.5]dec-3-en-1-yl]benzamide
-
-
5-[2-amino-4-(4-methoxy-3-methylphenyl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl]biphenyl-2-carbonitrile
-
-
5-[2-amino-4-(biphenyl-3-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl]-2-methoxybenzonitrile
-
-
6,7-furano-5,8a-dimethoxy hydrocoumaric acid methyl ester
-
inhibits 57.2% of the BACE1 activity at a concentration of 1 mM
6,7-furano-5-methoxy hydrocoumaric acid
-
-
6,7-furano-5-methoxy hydrocoumaric acid methyl ester
-
-
6,7-furano-5-prenyloxy hydrocoumaric acid
-
-
6,7-furano-5-prenyloxy hydrocoumaric acid methyl ester
-
-
6,7-furano-8,8a-dimethoxy hydrocoumaric acid methyl ester
-
inhibits 48.3% of the BACE1 activity at a concentration of 1 mM
6,7-furano-8-methoxy hydrocoumaric acid
-
-
6,7-furano-8-methoxy hydrocoumaric acid methyl ester
-
inhibits 36.4% of the BACE1 activity at a concentration of 1 mM
6,7-furano-8a-methoxy-5-prenyloxy hydrocoumaric acid
-
-
6,7-furano-8a-methoxy-5-prenyloxy hydrocoumaric acid methyl ester
-
competitive-type inhibitor
6-([2-(2-chlorophenyl)-5-[4-(1,3-thiazol-2-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
3.4% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(hexyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
13% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pentyloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
31% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pyrazin-2-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
46.6% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pyridazin-3-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
10.4% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pyridin-2-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
6.61% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pyridin-3-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
7.1% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pyridin-4-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
7.22% inhibition at 0.0125 mM
6-([2-(2-chlorophenyl)-5-[4-(pyrimidin-2-yloxy)phenyl]-1H-pyrrol-1-yl]methyl)pyridin-2-amine
-
9.7% inhibition at 0.0125 mM
6-fluoro-2-(3-(7-fluoroimidazo[1,2-a]pyridin-2-yl)phenyl)-1H-benzo[d]imidazole
-
inhibitor of BACE1, EC 3.4.23.46. 200fold more effective on BACE1 than BACE2
6-fluoro-2-(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-1H-benzo-[d]imidazole
-
inhibitor of BACE1, EC 3.4.23.46. 100fold more effective on BACE1 than BACE2
6-[(2,5-diphenyl-1H-pyrrol-1-yl)methyl]pyridin-2-amine
-
15% inhibition at 0.0125 mM
6-[(3R,4S)-3-benzyl-4-hydroxy-5-oxo-5-[[3-(2H-tetrazol-5-yl)phenyl]amino]pentanoyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-4-oxo-4H-pyran-2-carboxamide
-
76% inhibition at 2 microM
6-[[2-(2-chlorophenyl)-5-(4-methoxyphenyl)-1H-pyrrol-1-yl]methyl]pyridin-2-amine
-
30% inhibition at 0.0125 mM
6-[[2-(2-chlorophenyl)-5-(4-phenoxyphenyl)-1H-pyrrol-1-yl]methyl]pyridin-2-amine
-
16% inhibition at 0.0125 mM
6-[[2-(2-chlorophenyl)-5-(4-propoxyphenyl)-1H-pyrrol-1-yl]methyl]pyridin-2-amine
-
48% inhibition at 0.0125 mM
6-[[2-(4-butoxyphenyl)-5-(2-chlorophenyl)-1H-pyrrol-1-yl]methyl]pyridin-2-amine
-
31% inhibition at 0.0125 mM
7-phloroethol
-
significant BACE1 inhibition in a dose-dependent manner
8,8-diphenyl-2,3,4,8-tetrahydroimidazo[1,5-a]pyrimidin-6-amine
-
-
8-(biphenyl-4-ylmethyl)-4-(cyclohexylamino)-1-(4-fluorobenzyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one
-
-
8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one
-
-
8-C-glucosyl-(R)-aloesol
-
39.2% inhibition at 0.1 mM
8-C-glucosyl-7-methoxy-(R)-aloesol
-
26.8% inhibition at 0.1 mM
8-C-glucosyl-7-O-methylaloediol
-
-
AD115
-
a fragment of Gleevec
AD28
-
a fragment of Gleevec
AD94
-
a fragment of Gleevec
AD95
-
a fragment of Gleevec, strong inhibition
allo-aloeresin D
-
-
aloeresin D
-
71.5% inhibition at 0.1 mM
aloesin
-
37.5% inhibition at 0.1 mM
BACEi-II
-
inhibition may protect neurons from death induced by okadaic acid
benzyl 1-(3-acetoxypropyl)-5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-(dimethylamino)-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-(isopropyl(methyl)amino)-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-ethoxy-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-2,4-dimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-methoxy-2-oxoethyl)-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethyl-1-(2-morpholino-2-oxoethyl)-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethyl-1-(methylsulfonyl)-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-1-(methylsulfonyl)-4-phenyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-1-(methylsulfonyl)-4-propyl-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-4-ethyl-2,6-dimethyl-1-(methylsulfonyl)-1,4-dihydropyridine-3-carboxylate
-
-
benzyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-4-isopropyl-2,6-dimethyl-1-(methylsulfonyl)-1,4-dihydropyridine-3-carboxylate
-
-
benzyl [(2S)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]carbamate
-
-
benzyl [2-([1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl]amino)-2-oxo-1-[[(1-propylbutyl)sulfonyl]methyl]ethyl]carbamate
-
-
beta-secretase inhibitor IV
-
complete inhibition at 0.001 mM
beta-secretase inhibitor-II
-
-
C-2'-decoumaroyl-aloeresin G
-
72.0% inhibition at 0.1 mM
CA074Me
-
treatment of London APP transgenic mouse model of Alzheimer's disease that expresses human amyloid precursor protein containing the wild-type beta-secretase site results in substantial improvement in memory deficit assessed by the Morris water maze test. Improved memory function is accompanied by reduced amyloid plaque load, decreased amyloid beta40 and amyloid beta42, and reduced C-terminal beta-secretase fragment derived from amyloid precursor protein by beta-secretase. Inhibitor has no effects on any of these parameters in mice expressing the Swedish mutant beta-secretase site of amyloid precursor protein
cis-4-[(13S)-15-amino-13-cyclohexyl-11-oxo-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-10-yl]cyclohexanecarboxylic acid
-
-
dieckol
-
significant BACE1 inhibition in a dose-dependent manner
dioxinodehydroeckol
-
significant BACE1 inhibition in a dose-dependent manner
E64d
-
treatment of London APP transgenic mouse model of Alzheimer's disease that expresses human amyloid precursor protein containing the wild-type beta-secretase site results in substantial improvement in memory deficit assessed by the Morris water maze test. Improved memory function is accompanied by reduced amyloid plaque load, decreased amyloid beta40 and amyloid beta42, and reduced C-terminal beta-secretase fragment derived from amyloid precursor protein by beta-secretase. Inhibitor has no effects on any of these parameters in mice expressing the Swedish mutant beta-secretase site of amyloid precursor protein
eckol
-
significant BACE1 inhibition in a dose-dependent manner
EMD 565788
-
specific BACE1 inhibitor
EVD(statine)VAEF
EVE(statine)VAEF
EVG(statine)VAEF
EVL(statine)VAEF
EVNLAAEF
EVW(statine)VAEF
EVY(statine)VAEF
Gleevec
-
-
GRL-8234
heparin
-
leads to increased autocatalytic cleavage of beta-secretase and a subsequent loss of enzyme activity in vitro
Heparin sulfate
-
heparin sulfate analogue derived from porcine mucosal intestinal heparin are effective beta-secretase inhibitors, but have negligible activity as anticoagulants or as inhibitors of other aspartyl proteases structurally related to beta-secretase. The structure of the polysaccharide is important for the interaction with beta-secretase, not simply the level of sulfation or charge
imperatorin
isoimperatorin
-
-
isopropyl 2-(3-((2S,3R)-3-hydroxy-4-(3-methoxyphenylamino)-1-phenylbutan-2-ylcarbamoyl)-5-((R)-1-phenylethylcarbamoyl)-4-propylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-4-methyl-5-((R)-1-phenylethylcarbamoyl)pyridin-1(4H)-yl) acetate
-
-
isopropyl 2-(3-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-5-((R)-1-phenylethylcarbamoyl)-4-propylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-3-hydroxy-4-(3-methoxybenzylamino)-1-phenyl butan-2-ylcarbamoyl)-2,6-dimethyl-4-propylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-3-hydroxy-4-(3-methoxybenzylamino)-1-phenylbutan-2-ylcarbamoyl)-2,4-dimethylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-3-hydroxy-4-(3-methoxyphenylamino)-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-4-propylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(3-fluorophenylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(3-fluorophenylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4-dimethylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(3-fluorophenylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-4-propylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,4,6-trimethylpyridin-1(4H)-yl)acetate
-
-
isopropyl 2-(3-acetyl-5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-2,6-dimethyl-4-propylpyridin-1(4H)-yl)acetate
-
-
KTEEISEVN(statine)VAEF
KTEETSEVN(statine)VAEF
-
i.e. P10-P40 StatVal, activity completely abolished using saturating dose of 2.1 microM of the inhibitor, cleavage products of beta-secretase measured by fluoresence assay
kuwanon
-
prenylated flavone from the stem bark of Morus lhou, noncompetitive
kuwanon A
-
prenylated flavone from the stem bark of Morus lhou, noncompetitive
L-alpha-glutamyl-L-leucyl-N-[(2S,5S,8S,14R)-2-carboxy-5-(carboxymethoxy)-13-hydroxy-11,16-dimethyl-13-oxido-4,7,10-trioxo-1-phenyl-8-(propan-2-yl)-3,6,9-triaza-13-lambda5-phosphaheptadecan-14-yl]-L-alpha-asparagine
-
-
L-alpha-glutamyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-di-2H-tetrazol-5-ylphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.002 mM, 99.7% inhibition
L-alpha-glutamyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3,5-dicarboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.002 mM, 98.3% inhibition
L-alpha-glutamyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3-carbamoylphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.002 mM, 29.2% inhibition; 0.002 mM, 62.1% inhibition
L-alpha-glutamyl-L-valyl-N-((1S,2R)-1-benzyl-3-[(3-carboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-L-leucinamide
-
0.002 mM, 83.7% inhibition
L-alpha-glutamyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-([3-(4-methyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]amino)-3-oxopropyl]-L-leucinamide
-
0.002 mM, 74.2% inhibition
L-alpha-glutamyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(2H-tetrazol-5-yl)phenyl]amino)propyl]-L-leucinamide
-
0.002 mM, 92.2% inhibition
L-alpha-glutamyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]amino)propyl]-L-leucinamide
-
0.002 mM, 94.4% inhibition
L-alpha-glutamyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(5-oxo-4,5-dihydro-1,2,4-thiadiazol-3-yl)phenyl]amino)propyl]-L-leucinamide
-
0.002 mM, 91.9% inhibition
L-alpha-glutamyl-L-valyl-N-[(1S,2R)-1-benzyl-2-hydroxy-3-oxo-3-([3-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]amino)propyl]-L-leucinamide
-
-
luteolin
-
isolated from methanolic extracts of Perilla frutescens
LY2039911
Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-(statine)-Val-Ala-Glu-Phe-OH
-
-
Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe
-
complete inhibition at 0.1 mM
Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-[statine(3S,4S)]-Val-Ala-Glu-Phe-OH
-
-
memantine
-
-
methyl [(2S)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]carbamate
-
-
morusin
-
prenylated flavone from the stem bark of Morus lhou, noncompetitive
N'-[(2S,3R)-1-(3,5-difluorophenyl)-3-hydroxy-4-[(3-iodobenzyl)amino]butan-2-yl]-5-methyl-N,N-dipropylbenzene-1,3-dicarboxamide
-
-
N'-[(2S,3R)-3-hydroxy-4-[(3-iodobenzyl)amino]-1-phenylbutan-2-yl]-N,N-dipropylbenzene-1,3-dicarboxamide
-
-
N'-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-N,N-dipropylbenzene-1,3-dicarboxamide
-
-
N,N'-bis(3-cyano-4,5,6,7,8,9-hexahydrocycloocta[b]thiophen-2-yl)-2,2,3,3,4,4,5,5-octafluorohexanediamide
-
87% inhibition at 0.1 mM
N- [N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine tert-butyl ester
-
complete inhibition at 0.1 mM
N-((1S,2R)-1-benzyl-3-cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
N-(2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl)methanesulfonamide
-
-
N-(2-methylpropyl)-N2-([17-[(methylsulfonyl)(propyl)amino]-2-oxo-3-azatricyclo[13.3.1.16,10]icosa-1(19),6(20),7,9,15,17-hexaen-4-yl]methyl)-L-norleucinamide
-
-
N-(4-([4-(cyclohexylamino)-1-(3-fluorophenyl)-2-oxo-1,3,8-triazaspiro[4.5]dec-3-en-8-yl]methyl)phenyl)acetamide
-
-
N-(4-fluorophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e]-[1,4]diazepine-3-carboxamide
-
-
N-(4-[1-[(6-aminopyridin-2-yl)methyl]-5-(2-chlorophenyl)-1H-pyrrol-2-yl]phenyl)pyrimidin-5-amine
-
9.8% inhibition at 0.0125 mM
N-(5-([6-(4-(N,N-dimethyl)aminophenyl)pyrimidin-4-yl]amino)-2-methylphenyl)-N-methylmethanesulfonamide
-
-
N-(5-[[6-(2,3-dihydro-1,4-benzodioxin-6-yl)pyrimidin-4-yl]amino]-2-methylphenyl)-N-methylmethanesulfonamide
-
-
N-(tert-butoxycarbonyl)-L-isoleucyl-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
no inhibition at 0.01 mg/ml
N-(tert-butoxycarbonyl)-L-isoleucyl-N-[(4S,5S,7R)-8-(benzylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-phenylalaninamide
-
no inhibition at 0.01 mg/ml
N-(tert-butoxycarbonyl)-L-leucyl-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
54.57% inhibition at 0.01 mg/ml
N-(tert-butoxycarbonyl)-L-leucyl-N-[(4S,5S,7R)-8-(benzylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-phenylalaninamide
-
0.91% inhibition at 0.01 mg/ml
N-(tert-butoxycarbonyl)-L-valyl-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
no inhibition at 0.01 mg/ml
N-(tert-butoxycarbonyl)-L-valyl-N-[(4S,5S,7R)-8-(benzylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-phenylalaninamide
-
no inhibition at 0.01 mg/ml
N-(tert-butoxycarbonyl)valyl-N-[(2S,4R)-2-hydroxy-4-methyl-5-([(1S)-2-methyl-1-[(1-methylethyl)carbamoyl]propyl]amino)-1-(2-methylpropyl)-5-oxopentyl]-L-methioninamide
-
-
N-acetyl-beta-alanyl-3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
-
-
N-acetyl-L-alanyl-N-[(4S,5S,7R)-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-methioninamide
-
-
N-acetyl-L-leucyl-N-[(4S,5S,7R)-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-alaninamide
-
-
N-acetyl-L-leucyl-N-[(4S,5S,7R)-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-methioninamide
-
-
N-acetyl-L-valyl-N-[(4S,5S,7R)-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-L-methioninamide
-
-
N-benzyloxycarbonyl-Val-Leu-leucinal
-
-
N-[(1R,2S)-1-benzyl-2-hydroxy-3-[[3-(trifluoromethyl)benzyl]amino]propyl]-3-(1,1-dioxido-1,2-thiazinan-2-yl)-5-(ethylamino)-2-fluorobenzamide
-
-
N-[(1S)-1-[(butylsulfonyl)methyl]-2-([1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]amino)-2-oxoethyl]benzamide
-
-
N-[(1S,2R)-1-benzyl-2-hydroxy-3-[(3-ethoxybenzyl)amino]propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
N-[(1S,2R,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-4-methoxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]-4-oxo-6-[[(4S)-4-phenyl-1,3-oxazolidin-3-yl]carbonyl]-1,4-dihydropyridine-2-carboxamide
-
i.e. KMI-1030, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
N-[(1S,2S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]-4-oxo-6-[[(4S)-4-phenyl-1,3-oxazolidin-3-yl]carbonyl]-4H-pyran-2-carboxamide
-
i.e. KMI-1027, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
N-[(1S,2S)-1-benzyl-2-hydroxy-3-oxo-3-[[3-(2H-tetrazol-5-yl)phenyl]amino]propyl]-6-[[(4S)-4-phenyl-1,3-oxazolidin-3-yl]carbonyl]pyridine-2-carboxamide
-
i.e. KMI-1023, BACE1 inhibitors with a 5-membered ring at the P3 position and their BACE1 inhibitory activities summarized
N-[(1S,2S,4R)-2-azido-4-((S)-1-benzylcarbamoyl-2-methyl-propylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-4-methoxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-4-(2-methoxy-ethoxy)-butyl]-5-(methanesulfonyl-methylamino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-4-propyloxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-4-ethyloxy-2-hydroxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-2-amino-1-(3,5-difluoro-phenoxymethyl)-4-methoxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-4-allyloxy-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-4-benzyloxy-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-4-cyclopropylmethoxy-1-(3,5-difluorophenoxymethyl)-2-hydroxy-butyl]-5-(methanesulfonylmethyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
-
N-[(1S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-4-methoxybutyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenylethyl)-isophthalamide
-
-
N-[(1Z)-amino(butylamino)methylidene]-2-[2-(2-chlorophenyl)-5-(4-propoxyphenyl)-1H-pyrrol-1-yl]acetamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-2-methylbenzamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-3-hydroxybenzamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-4-(trifluoromethyl)benzamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-4-methoxybenzamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]-4-methylbenzamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]benzamide
-
-
N-[(2R)-1-([1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]pyridine-2-carboxamide
-
-
N-[(2R)-2-amino-1-benzyl-3-fluoropropyl]-2-[[(2-methylcyclopropyl)methyl]amino]-6-[methyl[(1-methylethyl)sulfonyl]amino]pyridine-4-carboxamide
-
-
N-[(2S)-1-([(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]amino)-1-oxo-3-phenylpropan-2-yl]naphthalene-1-carboxamide
-
no inhibition at 0.01 mg/ml
N-[(2S)-1-([(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]amino)-3-(4-nitrophenyl)-1-oxopropan-2-yl]naphthalene-1-carboxamide
-
no inhibition at 0.01 mg/ml
N-[(2S)-1-[[(2S,3S)-1-(butan-2-ylamino)-3-hydroxy-1-oxohexan-2-yl]amino]-3-phenylpropan-2-yl]-7-ethyl-1-methyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxamide 2,2-dioxide
-
compound designed specifically to interact with S1' active site residues to provide selectivity over memapsin 1 and cathepsin D. Inhibitor exhibits exceedingly potent inhibitory activity and high selectivity over BACE 2 and cathepsin D
N-[(2S)-1-[[(3S)-1-(butan-2-ylamino)-3-hydroxy-1-oxobutan-2-yl]amino]-3-phenylpropan-2-yl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
-
compound designed specifically to interact with S1' active site residues to provide selectivity over memapsin 1 and cathepsin D. Inhibitor exhibits exceedingly potent inhibitory activity and high selectivity over BACE 2 and cathepsin D
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]-1H-imidazole-2-carboxamide
-
-
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]-4-hydroxypyridine-3-carboxamide
-
-
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]-5-methyl-1H-pyrazole-3-carboxamide
-
-
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]pyrazine-2-carboxamide
-
-
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]pyridine-3-carboxamide
-
-
N-[(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]pyridine-4-carboxamide
-
-
N-[(2S,3R)-1-(3,5-difluorophenyl)-3-hydroxy-4-[(3-iodobenzyl)amino]butan-2-yl]-3-methylbenzamide
-
-
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-3-(phenylsulfonyl)propanamide
-
-
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-3-(piperidin-1-ylsulfonyl)propanamide
-
-
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-3-[(3-methylbutyl)sulfamoyl]propanamide
-
-
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-3-[(3-methylbutyl)sulfonyl]propanamide
-
-
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-4-(phenylsulfonyl)butanamide
-
-
N-[(2S,3R)-3-hydroxy-4-[(3-methoxybenzyl)amino]-1-phenylbutan-2-yl]-4-(piperidin-1-ylsulfonyl)butanamide
-
-
N-[(2S,3S)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-yl]-N'-[(1R)-1-(4-fluorophenyl)ethyl]-5-[(methylsulfonyl)amino]benzene-1,3-dicarboxamide
-
-
N-[(2S,3S,5R)-6-[[(2S)-1-(benzylamino)-3-methyl-1-oxobutan-2-yl]amino]-1-(3,5-difluorophenoxy)-3-hydroxy-5-methoxy-6-oxohexan-2-yl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
-
-
N-[(2S,4R)-2-hydroxy-4-methyl-5-([(1S)-2-methyl-1-[(2-methylpropyl)carbamoyl]propyl]amino)-1-(2-methylpropyl)-5-oxopentyl]-5-[methyl(methylsulfonyl)amino]-N'-(1-phenylethyl)benzene-1,3-dicarboxamide
-
-
N-[(3S,6S,13R)-13-[(3-[[(2S)-1-[[(1S)-1-(carboxymethoxy)-2-[[(1S)-1-carboxy-2-phenylethyl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-methyl-3-oxopropyl)(hydroxy)phosphoryl]-3-(carboxymethyl)-2,5-dioxo-1,4-diazacyclotridecan-6-yl]-L-alpha-glutamine
-
-
N-[(4S)-4-[(1R)-1-hydroxy-2-([1-[3-(propan-2-yl)phenyl]cyclopropyl]amino)ethyl]-2-oxo-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-19-yl]-N-methylpropane-1-sulfonamide
-
-
N-[(4S)-4-[(1R)-1-hydroxy-2-[[3-(propan-2-yl)benzyl]amino]ethyl]-2-oxo-11-oxa-3,16-diazatricyclo[15.3.1.1(6,10)]docosa-1(21),6(22),7,9,17,19-hexaen-19-yl]-N-methylpropane-1-sulfonamide
-
-
N-[(4S,5S,7R)-2-[7-(1-benzylpiperidin-4-yl)]methylcarbamoyl-5-hydroxy-2-methyloct-4-yl]-N'-[(R)-1-(4-fluorophenyl)ethyl-5-methyl(methylsulfonyl)amino]isophthalamide
-
-
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-Nalpha-(4-nitrobenzoyl)-L-phenylalaninamide
-
10.48% inhibition at 0.01 mg/ml
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-Nalpha-[(2Z)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
37.22% inhibition at 0.01 mg/ml
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-Nalpha-[(2Z)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]-L-phenylalaninamide
-
0.13% inhibition at 0.01 mg/ml
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-Nalpha-(4-nitrobenzoyl)-L-phenylalaninamide
-
1.47% inhibition at 0.01 mg/ml
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-Nalpha-[(2Z)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
22.83% inhibition at 0.01 mg/ml
N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-Nalpha-[(2Z)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]-L-phenylalaninamide
-
59.66% inhibition at 0.01 mg/ml
N-[(4S,5S,7R)-8-(benzylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-Nalpha-(tert-butoxycarbonyl)-L-phenylalaninamide
-
22.96% inhibition at 0.01 mg/ml
N-[(5R)-5-amino-5-methyl-4,16-dioxo-14-phenyl-3-oxa-15-azatricyclo[15.3.1.17,11]docosa-1(21),7(22),8,10,17,19-hexaen-19-yl]-N-methylmethanesulfonamide
-
-
N-[(Z)-[(4,6-dimethylpyrimidin-2-yl)amino][(3-nitrophenyl)amino]methylidene]-10H-phenothiazine-10-carboxamide
-
80% inhibition at 0.1 mM
N-[1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl]-5-methyl-N'-propylbenzene-1,3-dicarboxamide
-
-
N-[1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl]-5-methyl-N'-propylbenzene-1,3-dicarboxamide
-
-
N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[(6-[[4,6-di(piperidin-1-yl)-1,3,5-triazin-2-yl]amino]-1,3-benzothiazol-2-yl)sulfanyl]acetamide
N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-3,4-dichloro-N-phenylbenzamide
-
-
N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-4-methoxy-N-phenylbenzamide
-
-
N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-N-(2-phenylethyl)benzamide
-
-
N-[5-(2,3-dichlorobenzyl)-1,3-thiazol-2-yl]-4-([[4-phenyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl]methyl)benzamide
-
78% inhibition at 0.1 mM
N1-((2S,3S)-4-(4-(diethylcarbamoyl)-1H-pyrazol-1-yl)-3-hydroxy-1-phenylbutan-2-yl)-N3-((R)-1-(4-fluorophenyl)ethyl)-5-(N-methylmethylsulfonamido)isophthalamide
-
compound exhibits good inhibition effects on amyloid beta production in the cell-based assay
N1-((R)-1-(4-fluorophenyl)ethyl)-N3-((2S,3S)-3-hydroxy-4-(4-((R)-1-hydroxy ethyl)-1H-1,2,3-triazol-1-yl)-1-phenylbutan-2-yl)-5-(N-methylmethylsulfonamido)isophthalamide
-
-
N1-[1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl]-N3-propylbenzene-1,3,5-tricarboxamide
-
-
N1-[1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl]-N3-propylbenzene-1,3,5-tricarboxamide
-
-
N2-acetyl-3-(butylsulfonyl)-N-[(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]-D-alaninamide
-
-
N2-[(2R,4S)-5-[[N-[[(2,5-dimethyl-1,3-oxazol-4-yl)methoxy]carbonyl]-3-(methylsulfonyl)-L-alanyl]amino]-4-hydroxy-2,7-dimethyloctanoyl]-N-(2-methylpropyl)-L-valinamide
-
-
N2-[(2R,4S)-5-[[N-[[(3,5-dimethyl-1H-pyrazol-1-yl)methoxy]carbonyl]-3-(methylsulfonyl)-L-alanyl]amino]-4-hydroxy-2,7-dimethyloctanoyl]-N-(2-methylpropyl)-L-valinamide
-
-
N3-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-yl)-2,4,6-trimethyl-1-(methylsulfonyl)-N5-((R)-1-phenylethyl)-1,4-dihydropyridine-3,5-dicarboxamide
-
-
N3-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-yl)-4-ethyl-2,6-dimethyl-1-(methylsulfonyl)-N5-((R)-1-phenylethyl)-1,4-dihydropyridine-3,5-dicarboxamide
-
-
Nalpha-(1,3-benzodioxol-5-ylcarbonyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
-
40.29% inhibition at 0.01 mg/ml
Nalpha-(1,3-benzodioxol-5-ylcarbonyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
16.2% inhibition at 0.01 mg/ml
Nalpha-(2,4-dichlorobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
-
22.23% inhibition at 0.01 mg/ml
Nalpha-(2,4-dichlorobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
20.26% inhibition at 0.01 mg/ml
Nalpha-(3,4-dimethoxybenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
-
18.3% inhibition at 0.01 mg/ml
Nalpha-(3,5-dinitrobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
-
7.61% inhibition at 0.01 mg/ml
Nalpha-(3,5-dinitrobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
0.91% inhibition at 0.01 mg/ml
Nalpha-(3-chlorobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
-
25.66% inhibition at 0.01 mg/ml
Nalpha-(3-chlorobenzoyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
16.92% inhibition at 0.01 mg/ml
Nalpha-(tert-butoxycarbonyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-4-nitro-L-phenylalaninamide
-
30.06% inhibition at 0.01 mg/ml
Nalpha-(tert-butoxycarbonyl)-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
25.76% inhibition at 0.01 mg/ml
Nalpha-benzoyl-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[(2-methylpropyl)amino]-8-oxooctan-4-yl]-L-phenylalaninamide
-
11.2% inhibition at 0.01 mg/ml
NB-216
-
-
NB-544
-
-
OM00-3
OM99-2
pepstatin A
-
less potent inhibitor
phlorofurofucoeckol-A
-
significant BACE1 inhibition in a dose-dependent manner
Phloroglucinol
-
significant BACE1 inhibition in a dose-dependent manner
pyridin-3-ylmethyl [(2S)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]carbamate
-
-
pyridin-4-ylmethyl [(2S)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-3-(heptan-4-ylsulfonyl)-1-oxopropan-2-yl]carbamate
-
-
quercetin
-
significant BACE1 inhibition in a dose-dependent manner
rebaichromone
-
-
reticulon 3
-
-
-
reticulon 4
-
-
-
rosmarinic acid
-
isolated from methanolic extracts of Perilla frutescens
S-(tetrahydrofuran-3-yl) [(2S)-3-(butylsulfonyl)-1-([(2S,3R)-1-(3,5-difluorophenyl)-4-[(3-ethylbenzyl)amino]-3-hydroxybutan-2-yl]amino)-1-oxopropan-2-yl]carbamothioate
-
-
tert-butyl 5-((2S,3R)-3-hydroxy-4-(3-methoxyphenylamino)-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-4-propyl-1,4-dihydropyridine-3-carboxylate
-
-
tert-butyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-4-methyl-1,4-dihydropyridine-3-carboxylate
-
-
tert-butyl 5-((2S,3R)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-ylcarbamoyl)-1-(2-isopropoxy-2-oxoethyl)-4-propyl-1,4-dihydropyridine-3-carboxylate
-
-
tert-butyl [(2S)-1-[[(4S,5S,7R)-8-(benzylamino)-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamate
-
50.53% inhibition at 0.01 mg/ml
trans-4-[(13S)-15-amino-13-cyclohexyl-11-oxo-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-10-yl]cyclohexanecarboxylic acid
-
-
triphloroethol A
-
significant BACE1 inhibition in a dose-dependent manner
Z-DEVD-FMK
-
caspase-3 inhibitor Z-DEVD-FMK reduces BACE1 mRNA and protein levels, and inhibits its protease activity, thereby decreasing the amount of amyloid precursor protein C99 and beta-amyloid in ischemic brains
[(1R,2R,4R,5S,6S)-2-hydroxy-7-sulfo-4-[(sulfooxy)methyl]-3-oxa-7-azabicyclo[4.1.0]hept-5-yl 2-O-sulfo-beta-D-glucopyranosiduronic acid]n
-
IC50: 0.000031 mg/ml
[(2R,4S,5S)-5-[N-(3,4-dimethoxy)benzoyl-L-phenylalanylamido]-4-hydroxy-2,7-dimethyloctan] N'-isobutyl amide
-
14.66% inhibition at 0.01 mg/ml
[2-(acetylamino)-2-deoxy-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
IC50: 0.00041 mg/ml
[2-(acetylamino)-2-deoxy-4-O-beta-D-glucopyranuronosyl-6-O-sulfo-beta-D-glucopyranose]n
-
IC50: 0.000091 mg/ml
[2-(acetylamino)-2-deoxy-6-O-sulfo-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
IC50: 0.000031 mg/ml
[2-amino-2-deoxy-6-O-sulfo-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
IC50: 0.000159 mg/ml
[2-deoxy-2-(butanoylamino)-6-O-sulfo-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
IC50: 0.000055 mg/ml
[2-deoxy-2-(propanoylamino)-6-O-sulfo-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
IC50: 0.000053 mg/ml
[2-deoxy-2-(sulfoamino)-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
IC50: 0.0001 mg/ml
[2-deoxy-4-O-(2,3-di-O-sulfo-beta-D-glucopyranuronosyl)-6-O-sulfo-2-(sulfoamino)-beta-D-glucopyranose]n
-
IC50: 0.000053 mg/ml
[2-deoxy-6-O-sulfo-2-(sulfoamino)-4-O-(2-O-sulfo-beta-D-glucopyranuronosyl)-beta-D-glucopyranose]n
-
porcine mucosal intestinal heparin, IC50: 0.000028 mg/ml
[3-([1-benzyl-2-hydroxy-3-[(1-methylethyl)amino]propyl]carbamoyl)-5-[(1-phenylethyl)carbamoyl]phenyl]methylsulfamic acid
-
-
[3-([1-benzyl-2-hydroxy-3-[(3-methylbenzyl)amino]propyl]carbamoyl)-5-[[(2,5-dimethyl-1,3-oxazol-4-yl)methyl]carbamoyl]phenyl]methylsulfamic acid
-
-
[3-[(1-[1-hydroxy-2-[(3-methoxybenzyl)amino]ethyl]-3-methylbutyl)carbamoyl]-5-[(1-phenylethyl)carbamoyl]phenyl]methylsulfamic acid
-
-
additional information
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
4-hydroxynonenal
induction of BACE1 expression under oxidative stress determined
bovine lung heparin
-
0.0001 mg/ml increases BACE1 activity by 1600%
-
etazolate
-
i.e. 1-ethyl-4-(N'-isopropylidene-hydrazino)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester, stimulates alpha-secretase activity
H2O2
induction of BACE1 expression under oxidative stress determined
heparan sulfate
-
0.0001 mg/ml increases BACE1 activity by 900%
heparin
mucosal heparin
-
0.0001 mg/ml increases BACE1 activity by 900%, heparin tetrasaccharide inhibits stimulation of proBACE1 by full-length mucosal heparin at concentrations of greater than 0.0005 mg/ml
-
poly-D-glutamic acid
-
0.0001 mg/ml increases BACE1 activity by 170%
-
polysialic acid
-
0.0001 mg/ml increases BACE1 activity by 160%
sphingoisine-1-phosphate
-
treatment by sphingosine kinase inhibitor, RNA interference knockdown of sphingosine kinase, or overexpression of sphingosine 1-phosphate degrading enzymes decrease BACE1 activity, which reduces amyloid beta production. Sphingosine-1-phosphate specifically binds to full-length BACE1 and increases its proteolytic activity, suggesting that cellular sphingosine 1-phosphate directly modulates BACE1 activity
sphingosine 1-phosphate
-
treatment by sphingosine kinase inhibitor, RNA interference knockdown of sphingosine kinase, or overexpression of sphingosine 1-phosphate degrading enzymes decrease BACE1 activity, which reduces amyloid beta production. Sphingosine-1-phosphate specifically binds to full-length BACE1 and increases its proteolytic activity, suggesting that cellular sphingosine 1-phosphate directly modulates BACE1 activity
additional information
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0045
((7-methoxycoumarin-4-yl)acetyl)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(2,4-dinitrophenyl)
-
pro-memapsin 2
0.055
7-methoxycoumarin-4-yl-SEVNLDAEFK-2,4-dinitrophenyl-RR
-
-
0.0054
Arg-Glu(5-[(2-aminoethyl)amino]-naphthalene-1-sulfonic acid)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(4-(4-dimethylaminophenylazo)benzoic acid)-Arg
-
pro-memapsin 2
1.71
EEISEVNLDAEFRG
-
in 44 mM acetic acid/6 mM Na-acetate pH 3.8, 10 mM beta-mercaptoethanol, at 37C; pH 3.8, 37C
0.00191 - 0.00832
M-2420 peptide
12.8
RE(EDANS)EVNLDAEFK(Dabcyl)R-NH2
-
-
4.07
SEVNLDAEFR
-
in 44 mM acetic acid/6 mM Na-acetate pH 3.8, 10 mM beta-mercaptoethanol, at 37C; pH 3.8, 37C
additional information
additional information
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.155
7-methoxycoumarin-4-yl-SEVNLDAEFK-2,4-dinitrophenyl-RR
Homo sapiens
-
-
17.6
EEISEVNLDAEFRG
Homo sapiens
-
in 44 mM acetic acid/6 mM Na-acetate pH 3.8, 10 mM beta-mercaptoethanol, at 37C; pH 3.8, 37C
0.000068
RE(EDANS)EVNLDAEFK(Dabcyl)R-NH2
Homo sapiens
-
-
10.7
SEVNLDAEFR
Homo sapiens
-
in 44 mM acetic acid/6 mM Na-acetate pH 3.8, 10 mM beta-mercaptoethanol, at 37C; pH 3.8, 37C
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
3.298
casein-FITC
Homo sapiens
-
free enzyme, pH and temperature not specified in the publication
163625
6.222
M-2420 peptide
Homo sapiens
-
free enzyme, pH and temperature not specified in the publication
41333
1.286
panvera peptide
Homo sapiens
-
free enzyme, pH and temperature not specified in the publication
163626
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000008
(13S)-15-amino-10,13-dicyclohexyl-19-fluoro-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-11-one
-
pH and temperature not specified in the publication
0.000012
(13S)-15-amino-10,13-dicyclohexyl-19-methoxy-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-11-one
-
pH and temperature not specified in the publication
0.000005
(13S)-15-amino-10,13-dicyclohexyl-2-oxa-10,14,16,19-tetraazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-11-one
0.000008
(14S)-16-amino-10-cyclohexyl-14-(propan-2-yl)-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
pH and temperature not specified in the publication
0.000022
(14S)-16-amino-14-(propan-2-yl)-10-(tetrahydro-2H-pyran-4-yl)-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
pH and temperature not specified in the publication
0.000017
(14S)-16-amino-14-cyclohexyl-10-(tetrahydro-2H-pyran-4-yl)-2-oxa-10,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-11-one
-
pH and temperature not specified in the publication
0.000186
(15R)-17-amino-11,15-dicyclohexyl-2-oxa-11,16,18-triazatetracyclo[14.5.3.1(3,7).0(19,23)]pentacosa-1(21),3(25),4,6,17,19,22-heptaen-12-one
-
pH and temperature not specified in the publication
0.000031
(15S)-17-amino-11,15-dicyclohexyl-2-oxa-11,16,18-triazatetracyclo[14.5.3.1(3,7).0(19,23)]pentacosa-1(21),3(25),4,6,17,19,22-heptaen-12-one
-
pH and temperature not specified in the publication
0.000014
(7S,12Z)-N-[(2S,4R)-2-hydroxy-4-methyl-5-[[(1S)-2-methyl-1-(phenylcarbamoyl)propyl]amino]-1-(2-methylpropyl)-5-oxopentyl]-4-(1-methylethyl)-2,5,9-trioxo-1-oxa-3,6,10-triazacyclohexadec-12-ene-7-carboxamide
-
-
0.000295
11-oxo-N-(pyridin-4-yl)-10,11-dihydro-5H-dibenzo[b,e][1,4]-diazepine-3-carboxamide
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.00006
16-amino-11-cyclohexyl-2-oxa-11,15,17-triazatetracyclo[13.5.3.1(3,7).0(18,22)]tetracosa-1(20),3(24),4,6,16,18,21-heptaen-12-one
-
pH and temperature not specified in the publication
0.000025
2-(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-6-methoxy-1Hbenzo[d]imidazole
-
pH 4.5, 25C
0.000309
3-(3H-imidazo[4,5-c]pyridin-2-yl)-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.000293
3-(5-(4-fluorophenyl)-1H-imidazol-2-yl)-5H dibenzo[b,e][1,4]diazepin-11(10H)-one
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.000348
3-(5-(pyridin-4-yl)-1H-imidazol-2-yl)-5H dibenzo[b,e][1,4]-diazepin-11(10H)-one
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.000244
3-(6-fluoro-1H-benzo[d]imidazol-2-yl)-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.0009
3-[2-amino-6-(phenylcarbonyl)quinazolin-3(4H)-yl]-N-cyclohexyl-N-methylpropanamide
-
-
0.000011
4-(2-amino-6-phenoxyquinazolin-3(4H)-yl)-N,4-dicyclohexyl-N-methylbutanamide
-
-
0.0113
6,7-furano-8a-methoxy-5-prenyloxy hydrocoumaric acid methyl ester
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.000017
6-fluoro-2-(3-(7-fluoroimidazo[1,2-a]pyridin-2-yl)phenyl)-1H-benzo[d]imidazole
-
pH 4.5, 25C
0.000034
6-fluoro-2-(3-(imidazo[1,2-a]pyridin-2-yl)phenyl)-1H-benzo-[d]imidazole
-
pH 4.5, 25C
0.00002
cis-4-[(13S)-15-amino-13-cyclohexyl-11-oxo-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-10-yl]cyclohexanecarboxylic acid
-
pH and temperature not specified in the publication
0.0018
GRL-8234
-
i.e. inhibitor 24, memapsin 2 enzyme inhibition assay
0.062
luteolin
-
-
0.000211
N-(4-fluorophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e]-[1,4]diazepine-3-carboxamide
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.0000018
N-[(1S,2R)-1-benzyl-2-hydroxy-3-[(3-ethoxybenzyl)amino]propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
-
pH 4.5, 37C
0.00021
N-[(1S,2R,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-4-methoxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.00007
N-[(1S,2S,4R)-2-azido-4-((S)-1-benzylcarbamoyl-2-methyl-propylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-4-methoxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.0000031
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-4-(2-methoxy-ethoxy)-butyl]-5-(methanesulfonyl-methylamino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.000003
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-4-propyloxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.0000021
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-4-ethyloxy-2-hydroxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.00014
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-2-amino-1-(3,5-difluoro-phenoxymethyl)-4-methoxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.0000033
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-4-allyloxy-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.00002
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-4-benzyloxy-1-(3,5-difluoro-phenoxymethyl)-2-hydroxy-butyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.0000013
N-[(1S,2S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-4-cyclopropylmethoxy-1-(3,5-difluorophenoxymethyl)-2-hydroxy-butyl]-5-(methanesulfonylmethyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.00013
N-[(1S,4R)-4-((S)-1-benzylcarbamoyl-2-methylpropylcarbamoyl)-1-(3,5-difluoro-phenoxymethyl)-4-methoxybutyl]-5-(methanesulfonyl-methyl-amino)-N'-((R)-1-phenylethyl)-isophthalamide
-
pH and temperature not specified in the publication
0.0000004
N-[(2S)-1-[[(2S,3S)-1-(butan-2-ylamino)-3-hydroxy-1-oxohexan-2-yl]amino]-3-phenylpropan-2-yl]-7-ethyl-1-methyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxamide 2,2-dioxide
-
inhibitor exhibits a cellular IC50 value of 15 nM. pH not specified in the publication, temperature not specified in the publication
0.000025
N-[(2S)-1-[[(3S)-1-(butan-2-ylamino)-3-hydroxy-1-oxobutan-2-yl]amino]-3-phenylpropan-2-yl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.00001
N-[(2S,3S)-4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-yl]-N'-[(1R)-1-(4-fluorophenyl)ethyl]-5-[(methylsulfonyl)amino]benzene-1,3-dicarboxamide
-
in 50 mM sodium acetate buffer, pH 4.5, at 25C
0.000001
N-[(2S,3S,5R)-6-[[(2S)-1-(benzylamino)-3-methyl-1-oxobutan-2-yl]amino]-1-(3,5-difluorophenoxy)-3-hydroxy-5-methoxy-6-oxohexan-2-yl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
-
Ki less than 0.000001 mM, pH and temperature not specified in the publication
0.0000011
N-[(2S,4R)-2-hydroxy-4-methyl-5-([(1S)-2-methyl-1-[(2-methylpropyl)carbamoyl]propyl]amino)-1-(2-methylpropyl)-5-oxopentyl]-5-[methyl(methylsulfonyl)amino]-N'-(1-phenylethyl)benzene-1,3-dicarboxamide
-
-
0.00000012
N2-[(2R,4S)-5-[[N-[[(2,5-dimethyl-1,3-oxazol-4-yl)methoxy]carbonyl]-3-(methylsulfonyl)-L-alanyl]amino]-4-hydroxy-2,7-dimethyloctanoyl]-N-(2-methylpropyl)-L-valinamide
-
-
0.0000003
N2-[(2R,4S)-5-[[N-[[(3,5-dimethyl-1H-pyrazol-1-yl)methoxy]carbonyl]-3-(methylsulfonyl)-L-alanyl]amino]-4-hydroxy-2,7-dimethyloctanoyl]-N-(2-methylpropyl)-L-valinamide
0.000001 - 0.0000098
OM99-2
0.039
rosmarinic acid
-
-
0.001
trans-4-[(13S)-15-amino-13-cyclohexyl-11-oxo-2-oxa-10,14,16-triazatetracyclo[12.5.3.1(3,7).0(17,21)]tricosa-1(19),3(23),4,6,15,17,20-heptaen-10-yl]cyclohexanecarboxylic acid
-
Ki above 0.001 mM, pH and temperature not specified in the publication
0.000425
[3-([1-benzyl-2-hydroxy-3-[(1-methylethyl)amino]propyl]carbamoyl)-5-[(1-phenylethyl)carbamoyl]phenyl]methylsulfamic acid
-
-
0.000552
[3-([1-benzyl-2-hydroxy-3-[(3-methylbenzyl)amino]propyl]carbamoyl)-5-[[(2,5-dimethyl-1,3-oxazol-4-yl)methyl]carbamoyl]phenyl]methylsulfamic acid
-
-
0.000916
[3-[(1-[1-hydroxy-2-[(3-methoxybenzyl)amino]ethyl]-3-methylbutyl)carbamoyl]-5-[(1-phenylethyl)carbamoyl]phenyl]methylsulfamic acid
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.2197
(+)-byakangelicin
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.1049
(+)-byakangelicol
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.3592
(+)-oxypeucedanin
Homo sapiens
-
in 50 mM sodium acetate, pH 4.5, at 25C
0.00311 - 0.1275
(-)-gallocatechin gallate
0.00017 - 0.0008
(1R,3S)-3-[(1S)-1-(acetylamino)-2-methylpropyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
0.0015 - 0.0027
(1R,3S)-3-[1-(acetylamino)cyclopentyl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
0.0038 - 0.0042
(1R,3S)-3-[2-(acetylamino)propan-2-yl]-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]cyclohexanecarboxamide
0.00037 - 0.0037
(1R,3S)-3-[2-(acetylamino)propan-2-yl]-N-[(2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-oxo-1-phenylhexan-2-yl]cyclohexanecarboxamide
0.0000025 - 0.00014
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(2-oxopiperidin-1-yl)propan-2-yl]cyclohexanecarboxamide
0.000025 - 0.00096
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(2-oxopyrrolidin-1-yl)propan-2-yl]cyclohexanecarboxamide
0.00058 - 0.0037
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-(propanoylamino)propan-2-yl]cyclohexanecarboxamide
0.00015 - 0.0002
(1R,3S)-N-[(2S,3S)-3-hydroxy-1-phenyl-4-[[3-(propan-2-yl)benzyl]amino]butan-2-yl]-3-[2-[methyl(propanoyl)amino]propan-2-yl]cyclohexanecarboxamide
0.000511
(1S,2R)-N-[1-benzyl-2-hydroxy-3-(S)-[(1-benzylpiperidin-4-yl)amino]-propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(R)-1-phenylethyl]isophthalamide
Homo sapiens
-
pH 4.0
0.000222
(1S,2R)-N-[1-benzyl-2-hydroxy-3-(S)-[2-(1-benzylpiperidin-4-yl)ethylamino]-propyl]-5-[methyl(methylsulfonyl)-amino]-N'-[(R)-1-(4-fluorophenyl)ethyl]isophthalamide
Homo sapiens
-
pH 4.0
0.000567
(1S,2R)-N-[1-benzyl-2-hydroxy-3-(S)-[2-(1-benzylpiperidin-4-yl)ethylamino]-propyl]-5-[methyl(methylsulfonyl)amino]-N'-[(R)-1-phenylethyl]isophthalamide
Homo sapiens
-
pH 4.0
0.00015
(2R,4S)-N-butyl-4-hydroxy-2-methyl-4-[(2S,5S,7R)-1,2,7-trimethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl]butanamide
Homo sapiens
-
-
0.00059
(2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7-dimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl]-4-hydroxy-2-methylbutanamide
Homo sapiens
-
-
0.00025
(2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7-dimethyl-3,16-dioxo-1,4-diazacyclohexadecan-5-yl]-4-hydroxy-2-methylbutanamide
Homo sapiens
-
-
0.000008
(2S)-2-((3R)-3-acetamido-3-isobutyl-2-oxo-1-pyrrolidinyl)-N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-2-(1,2,3,4-tetrahydro-3-isoquinolinyl)ethyl)-4-phenylbutanamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0056
(2S,5S,8S,11S,14S)-14-amino-5-benzyl-8-(cyclohexylmethyl)-16-(5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-2-hydroxy-11-(1-methylethyl)-4,7,10,13,16-pentaoxo-N-[3-(2H-tetrazol-5-yl)phenyl]-3,6,9,12-tetraazahexadecan-1-amide
Homo sapiens
-
i.e. KMI-574, used as a substrate transition-state mimic
0.000022
(3S,14R,16S)-16-[(1R)-1-hydroxy-2-([3-(1-methylethyl)benzyl]amino)ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,